• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » October 1994 - The CenterWatch Monthly : Volume 1, Issue 2, October 1994
October 1994 - The CenterWatch Monthly : Volume 1, Issue 2, October 1994

October 1994 - The CenterWatch Monthly : Volume 1, Issue 2, October 1994

$79.00

Product Details

Private Doctors Launch Nationwide Consortium

Affiliated Research Centers (ARC) represents 34 centers and 158 investigators.

Investigator-owned company eyes capturing 50 percent of market for urological clinical research.

The company expects to launch nationwide consortiums in 11 other fields.

Second Thoughts About Thought Leaders

Poor performance by Thought Leaders has drug companies rethinking how they should use them.

Analysis of large Phase III trial shows that the Thought Leaders performed poorly in terms of speed and quality, and were more expensive than average.

Sponsors have an opportunity to improve clinical trials process by making more judicious use of Thought Leaders.

Sponsors Turning More Critical of Investigators' Performance

Sponsors using more systematic methods to measure investigators' performance.

Over 35 U.S. pharmaceutical companies now using industry data base to compare center costs.

Sponsors using Freedom of Information Act to determine if investigators have been cited for deficiencies.

Sandoz Developing New Strategy for Siting Phase III Trials

"Portfolio" approach will rank candidate investigators based on past performance in three areas: speed, quality, and cost.

Only higher-ranked investigators will win contracts.

Study shows portfolio approach will result in improved data quality, lower study costs per patient, and quicker completion of Phase III trials.

  • Phase II Watch
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing